text:
package com.orangemuffin.quickremind.adapters;

import android.app.Activity;
import android.app.AlertDialog;
import android.content.Context;
import android.content.DialogInterface;
import android.content.Intent;
import android.content.res.Resources;
import android.support.v4.app.Fragment;
import android.support.v7.widget.RecyclerView;
import android.util.TypedValue;
import android.view.LayoutInflater;
import android.view.MenuInflater;
import android.view.MenuItem;
import android.view.View;
import android.view.ViewGroup;
import android.widget.ImageView;
import android.widget.PopupMenu;
import android.widget.RelativeLayout;
import android.widget.TextView;
import android.widget.Toast;

import com.orangemuffin.quickremind.R;
import com.orangemuffin.quickremind.activities.ReminderEditActivity;
import com.orangemuffin.quickremind.database.ReminderDatabase;
import com.orangemuffin.quickremind.fragments.FragmentEnded;
import com.orangemuffin.quickremind.fragments.FragmentUpcoming;
import com.orangemuffin.quickremind.models.Reminder;
import com.orangemuffin.quickremind.receivers.AlarmReceiver;
import com.orangemuffin.quickremind.utils.DateAndTimeUtil;
import com.orangemuffin.quickremind.utils.NotificationUtil;

import java.util.List;

/* Created by OrangeMuffin on 6/26/2017 */
public class ReminderAdapter extends RecyclerView.Adapter<ReminderAdapter.ViewHolder> {
    private List<Reminder> reminderList;
    private Context context;
    private Fragment parentFragment;

    public ReminderAdapter(List<Reminder> reminderList, Context context, Fragment parentFragment) {
        this.parentFragment = parentFragment;
        this.reminderList = reminderList;
        this.context = context;
    }

    @Override
    public int getItemCount() {
        return reminderList.size();
    }

    @Override
    public void onBindViewHolder(ReminderAdapter.ViewHolder viewHolder, int i) {
        Reminder reminder = reminderList.get(i);
        viewHolder.card_content.setText(reminder.getContent());

        int duedate = DateAndTimeUtil.getDueDate(reminder.getDate());

        //modify display date according to due date
        if (duedate == 0) {
            viewHolder.card_date_text.setText("Today");
        } else if (duedate == 1) {
            viewHolder.card_date_text.setText("Tomorrow");
        } else if (duedate == -1) {
            viewHolder.card_date_text.setText("Yesterday");
        } else {
            viewHolder.card_date_text.setText(reminder.getDate());
        }

        //display converted time
        viewHolder.card_time_text.setText(DateAndTimeUtil.convertTime("hh:mm a", reminder.getTime()));

        int separator_id = viewHolder.card_separator.getId();
        int content_id = viewHolder.card_content.getId();

        //configure repeat display
        if (reminder.getRepeat().equals("true")) {
            viewHolder.card_repeat_img.setVisibility(View.VISIBLE);
        } else {
            viewHolder.card_repeat_img.setVisibility(View.GONE);
        }
        if (reminder.getRepeat().equals("true") && reminder.getPersistent().equals("true")) {
            viewHolder.card_separator.setVisibility(View.VISIBLE);

            //rescale left and top margin on persistent icon for symmetry display
            RelativeLayout.LayoutParams params = rescaleView("dual", separator_id, content_id);
            viewHolder.card_persistent_img.setLayoutParams(params);
        } else {
            viewHolder.card_separator.setVisibility(View.GONE);
        }

        //configure persistent display
        if (reminder.getPersistent().equals("true")) {
            viewHolder.card_persistent_img.setVisibility(View.VISIBLE);

            //if single icon, need to reset params programmatically
            if (reminder.getRepeat().equals("false")) {
                RelativeLayout.LayoutParams params = rescaleView("single", separator_id, content_id);
                viewHolder.card_persistent_img.setLayoutParams(params);
            }
        } else {
            viewHolder.card_persistent_img.setVisibility(View.GONE);
        }
    }

    @Override
    public ReminderAdapter.ViewHolder onCreateViewHolder(ViewGroup viewGroup, int i) {
        View rootView = LayoutInflater.from(viewGroup.getContext()).inflate(R.layout.reminder_cardview, viewGroup, false);
        return new ViewHolder(rootView);
    }

    public class ViewHolder extends RecyclerView.ViewHolder {
        TextView card_content, card_date_text, card_time_text;
        ImageView card_date_img, card_time_img, card_repeat_img, card_persistent_img, overflow_more;
        View card_separator;

        RelativeLayout relativeLayout;

        public ViewHolder(View view) {
            super(view);

            relativeLayout = (RelativeLayout) view.findViewById(R.id.card_element);

            //setting up onClick for the entire layout
            relativeLayout.setOnClickListener(new View.OnClickListener() {
                @Override
                public void onClick(View view) {
                    showDisplay(getAdapterPosition());
                }
            });

            card_content = (TextView) view.findViewById(R.id.card_content);
            card_date_text = (TextView) view.findViewById(R.id.card_date_text);
            card_time_text = (TextView) view.findViewById(R.id.card_time_text);
            card_date_img = (ImageView) view.findViewById(R.id.card_date_img);
            card_time_img = (ImageView) view.findViewById(R.id.card_time_img);
            card_repeat_img = (ImageView) view.findViewById(R.id.card_repeat_img);
            card_persistent_img = (ImageView) view.findViewById(R.id.card_persistent_img);
            overflow_more = (ImageView) view.findViewById(R.id.overflow_more);
            card_separator = view.findViewById(R.id.card_separator);

            //setting up onClick for overflow icon
            overflow_more.setOnClickListener(new View.OnClickListener() {
                @Override
                public void onClick(View view) {
                    showPopupMenu(overflow_more, getAdapterPosition());
                }
            });
        }
    }

    //show reminder display dialog on layout click
    public void showDisplay(final int position) {
        final Reminder reminder = reminderList.get(position);
        AlertDialog.Builder dialog = new AlertDialog.Builder(context);
        LayoutInflater inflater = ((Activity) context).getLayoutInflater();
        View dialogView = inflater.inflate(R.layout.reminder_display_dialog, null);
        dialog.setView(dialogView);

        TextView content_text = (TextView) dialogView.findViewById(R.id.content_text);
        TextView date_text = (TextView) dialogView.findViewById(R.id.date_text);
        TextView date_text2 = (TextView) dialogView.findViewById(R.id.date_text2);
        TextView time_text = (TextView) dialogView.findViewById(R.id.time_text);
        TextView date_actual = (TextView) dialogView.findViewById(R.id.date_actual_text);
        TextView repeat_text = (TextView) dialogView.findViewById(R.id.repeat_text);
        ImageView repeat_img = (ImageView) dialogView.findViewById(R.id.repeat_img);
        TextView persistent_text = (TextView) dialogView.findViewById(R.id.persistent_text);
        ImageView persistent_img = (ImageView) dialogView.findViewById(R.id.persistent_img);

        //setting up static content
        content_text.setText(reminder.getContent());
        date_text.setText(DateAndTimeUtil.dateToDay(reminder.getDate()));
        date_text2.setText(DateAndTimeUtil.convertDate("dd MMMM yyyy", reminder.getDate()));
        time_text.setText("at " + DateAndTimeUtil.convertTime("hh:mm a", reminder.getTime()));

        //setting up due date indicator
        int duedate = DateAndTimeUtil.getDueDate(reminder.getDate());
        if (duedate == 0) {
            date_actual.setText("Today");
        } else if (duedate == 1) {
            date_actual.setText("Tomorrow");
        } else if (duedate == -1) {
            date_actual.setText("Yesterday");
        } else if (duedate > 1) {
            date_actual.setText("In " + duedate + " days");
        } else {
            date_actual.setText(Math.abs(duedate) + " days ago");
        }

        //setting up repeat display
        if (reminder.getRepeat().equals("false")) {
            repeat_img.setImageResource(R.drawable.ic_repeat_off_gray);
            repeat_text.setText("Do not Repeat");
        } else {
            repeat_text.setText("Every " + reminder.getRepeatNo() + " " + reminder.getRepeatType());
        }

        //setting up persistent display
        if (reminder.getPersistent().equals("true")) {
            persistent_text.setText("Persistent");
        } else {
            persistent_img.setImageResource(R.drawable.ic_pushpin_off_gray);
            persistent_text.setText("Not Persistent");
        }

        //setting up dialog buttons
        dialog.setPositiveButton("Ok", null);
        dialog.setNegativeButton("EDIT", new DialogInterface.OnClickListener() {
            @Override
            public void onClick(DialogInterface dialogInterface, int i) {
                openEditActivity(reminder.getId());
            }
        });
        dialog.setNeutralButton("DELETE", new DialogInterface.OnClickListener() {
            @Override
            public void onClick(DialogInterface dialogInterface, int i) {
                deleteReminder(reminder, position);
            }
        });

        AlertDialog alertDialog = dialog.create();
        alertDialog.show();
    }

    private void showPopupMenu(final View view, final int position) {
        final PopupMenu popupMenu = new PopupMenu(context, view);
        MenuInflater inflater = popupMenu.getMenuInflater();
        inflater.inflate(R.menu.menu_reminder, popupMenu.getMenu());

        final Reminder reminder = reminderList.get(position);

        //remove "stop repeating" button on conditions
        if (parentFragment instanceof FragmentEnded) {
            popupMenu.getMenu().getItem(0).setVisible(false);
        } else if (!reminder.getRepeat().equals("true")) {
            popupMenu.getMenu().getItem(0).setVisible(false);
        }

        popupMenu.setOnMenuItemClickListener(new PopupMenu.OnMenuItemClickListener() {
            @Override
            public boolean onMenuItemClick(MenuItem menuItem) {
                switch (menuItem.getItemId()) {
                    case R.id.stop:
                        new AlarmReceiver().cancelRepeating(context, reminder, new ReminderDatabase(context));
                        return true;
                    case R.id.show:
                        NotificationUtil.createNotification(context, reminder);
                        return true;
                    case R.id.edit:
                        openEditActivity(reminder.getId());
                        return true;
                    case R.id.delete:
                        deleteReminder(reminder, position);
                        return true;
                }
                return false;
            }
        });
        popupMenu.show();
    }

    public void openEditActivity(final int reminderID) {
        Intent intent = new Intent(context, ReminderEditActivity.class);
        intent.putExtra("REMINDER_ID", reminderID);
        context.startActivity(intent);
        ((Activity) context).overridePendingTransition(R.anim.slide_up, R.anim.anim_stay);
    }

    public void deleteReminder(final Reminder reminder, final int position) {
        AlertDialog.Builder dialogInner = new AlertDialog.Builder(context);
        String warning_text = "Are you sure you want to delete this reminder?";
        dialogInner.setMessage(warning_text);
        dialogInner.setPositiveButton("Yes", new DialogInterface.OnClickListener() {
            @Override
            public void onClick(DialogInterface dialogInterface, int i) {
                ReminderDatabase rb = new ReminderDatabase(context);

                //cancel reminder alarm using its ID
                new AlarmReceiver().cancelAlarm(context, reminder.getId());

                //delete reminder in the database
                rb.deleteReminder(reminder);

                //remove reminder in the displayed list
                reminderList.remove(position);

                //notify adapter of removed item
                notifyItemRemoved(position);
                notifyDataSetChanged();

                //update display if list is now empty
                if (parentFragment instanceof FragmentUpcoming) {
                    ((FragmentUpcoming) parentFragment).checkEmpty();
                } else if (parentFragment instanceof FragmentEnded) {
                    ((FragmentEnded) parentFragment).checkEmpty();
                }
            }
        });
        dialogInner.setNegativeButton("No", null);
        dialogInner.show();
    }

    public RelativeLayout.LayoutParams rescaleView(String mode, int separator_id, int content_id) {
        int wrap_content = RelativeLayout.LayoutParams.WRAP_CONTENT;
        RelativeLayout.LayoutParams params = new RelativeLayout.LayoutParams(wrap_content, wrap_content);
        if (mode.equals("dual")) { //display of 2 icon
            params.setMargins(0, (int) dpToPixel(6), 0, 0);
        } else { //single icon, reset params
            params.setMargins((int) dpToPixel(13), (int) dpToPixel(6), 0, 0);
        }
        params.width = (int) dpToPixel(17);
        params.height = (int) dpToPixel(17);
        params.addRule(RelativeLayout.RIGHT_OF, separator_id);
        params.addRule(RelativeLayout.BELOW, content_id);

        return params;
    }

    public float dpToPixel(int dp) {
        Resources r = Resources.getSystem();
        return TypedValue.applyDimension(TypedValue.COMPLEX_UNIT_DIP, dp, r.getDisplayMetrics());
    }
}


text:
#LSEThinks
Writing for LSE Brexit
Ros Taylor
Closing the Overton window: Brexit from gender and queer perspectives
The bulk of the debate and commentary on Brexit has focused broadly on matters such as trade and migration. Very little has so far been said about the way Brexit matters from gender and queer perspectives, write Moira Dustin, Nuno Ferreira and Susan Millns (University of Sussex). In this extract from their edited collection of essays, Gender and Queer Perspectives on Brexit, they predict that it will narrow the scope of policy debate around these issues, and put particularly disadvantaged groups – 'minorities within minorities' – at special risk.
The breakdown of voting in the referendum shows that, overall, men and women do have different views of Brexit (as do different generations). Furthermore, in the political sphere, and in terms of party politics, Brexit has seen opportunities created for female politicians and has paved the way for Britain's second female prime minister. Additionally, Brexit impacts upon a myriad of policy areas that are highly important to women and gender and sexual minorities – employment law, discrimination law, single market, free movement, migration, citizenship rights, to name but a few.
Brighton & Hove City Council Workers Forum hoist a Pride flag at Brighton Pride 2016. Photo: The Lilac Bonzai via a CC-BY-NC 2.0 licence
Our starting point for this collection was not any judgment on the desirability of the UK leaving the EU. Yet it is fair to say that none of the contributors is looking forward with enthusiasm to a post-Brexit world in which these groups have greater rights and freedoms, and where they are freed from the constraints of bureaucrats in Brussels. Rather, our writers express a range of views. Aisha Gill and Nazneen Ahmed bring to life the sense of shock felt by many women on hearing the referendum result. A number of contributors find cause for pessimism in the likelihood that leaving the EU will aggravate existing social or legal problems.
Nor is it the case that the UK was ever fully 'in' in the first place. To take the example of asylum, as Ingi Iusman points out, the UK opted out of the Family Reunification Directive and only signed up to the 2004 incarnation of the EU Qualification Directive, so is not signed up to the 2011 recast Directive with its extended recognition of both sexual orientation and gender identity. Additionally, as Christel Querton argues, opting into the 2004 Directive did not lead to a more inclusive and gender-sensitive approach to asylum. Thus, the 'risks' are less concrete and it is rather the case that UK citizens and residents will not benefit from what are currently unknown future enhanced rights and protections.
Nevertheless, there is also a strong sense of resistance and positivity about the potential for addressing some of these risks if only they are identified and publicly recognised. Solanke, for example, suggests an approach for ensuring that non-discrimination principles and policies apply equally to all children, whether or not they are migrants and regardless of their parents' nationality. Equally, Iusman argues that the UK could adopt the measures in the reformed Common European Asylum System to act in 'the best interests of the child'. Mary-Ann Stephenson and Marzia Fontana highlight the specific recommendations of the Women's Budget Group for avoiding regression in economic areas affecting women.
Are women and sexual and gender minorities likely to be more disadvantaged than other citizens and residents in the UK? One of the arguments in the taking-back-control camp is that the EU is heavily bureaucratic and imposes a high regulatory burden on its member states. The argument of many Remainers is that EU bureaucracy is very necessary protection for marginalised and disadvantaged individuals – including, disproportionately, women and sexual and gender minorities. So far, the UK government has not suggested that it will use exiting the EU as an opportunity for a regression on rights, whether or not they derive from Brussels.
Perhaps what these contributions show most strongly is that there is no value in talking about women or sexual or gender minorities as homogenous groups. Aside from gender and sexuality identifiers, individuals need to be seen as workers, consumers, public service users, carers, people seeking asylum, people from minority ethnic communities, people with disabilities, young people. The part of the UK they come from makes a difference.
To take one example, Dieuwertje Dyi Huijg highlights the importance of considering the impact of leaving the EU for disabled EU citizens and carers – the majority of whom are likely to be women but who are disadvantaged in different ways, because of who they are and what they do. Yet, as she convincingly explains, no one is inherently vulnerable. Rather, disabled people are 'vulnerabilised' by the state. The concept of being made vulnerable – and perhaps more vulnerable – by the fallout of leaving the EU may usefully be applied beyond disability to people historically marginalised because of ethnicity, nationality, religion or age, as well as gender and sexuality.
We are unlikely to see a bonfire of gender and LGBTQI+ equality protections. Yet, as Eugenia Caracciolo di Torella points out in relation to promoting a work-life balance, it is not 'just' about legislation. It is also about principles, values, discourse and the parameters of possibility. This is where the Overton window is a useful descriptor. As Amy Barrow suggests, while leaving the EU's Common Security and Defence Policy may not be as complex as withdrawal from other areas of EU policy, it may mean that momentum on mainstreaming gender in peace and security is lost and there is a return to the traditional assumption that gender is irrelevant to security matters. Combine this with the recognition that the Brexit debate in the UK has been dominated by militaristic language and metaphors from the world of business, and we see a narrow window of policy debate focused on winners and losers. Thus, we suggest that the Overton window is likely to shrink after Brexit.
Our conclusion is that the immediate threat is not to the broad categories of 'gay' or 'female' UK citizens or residents, but rather to those sometimes termed 'minorities within minorities' – BME families, disabled women, unaccompanied asylum-seeking boys, women living in the border regions of Northern Ireland. We hope that highlighting such threats will be the first step in addressing them.
This post is an edited extract from Gender and Queer Perspectives on Brexit, edited by Moira Dustin, Nuno Ferreira and Susan Millns (Palgrave Macmillan). It represents the views of the authors and not those of LSE.
Moira Dustin is a Research Fellow at the Sussex European Institute, University of Sussex.
Nuno Ferreira is a Professor of Law at the Sussex European Institute, University of Sussex.
Susan Millns is a Professor of Law at the Sussex European Institute, University of Sussex.
Posted In: Culture and civil society | Featured | Migration | UK and European law
Friedrich says:
I may have missed something here, but there is no definition of the Overton Window in this article. I looked the phrase up on Google, and see it refers, very broadly, to "the accepted range of political dialogue in a society".
Undoubtedly, as I see it, Brexit is an attempt to move the political centre of gravity in the UK to the right. It is an attempt to make the UK more like the US, and less like continental Europe. More radical, consensual, even feminine views would be marginalised, and the centre of political gravity would shift, as detailed above, to the more masculine ideas of business and the military, and the idea of winners and losers.
The popular press in the UK are, in my opinion, partly responsible for this. Even after Labour got only 10%, and the Conservatives 4%, in the recent Euro elections, the popular press are going on about leadership battles in the Labour and Tory parties, and the battle between Labour and the Tories. These issues seem increasingly irrelevant compared to the wider issues involved in Brexit.
Ros Taylor says:
Thanks, Friedrich. We probably should have defined it, as you are right – it isn't a phrase in common currency.
In the excitement of analysing Euro election results, I mistakenly gave the figures for MEPs elected (10 Labour, 4 Conservative) instead of the percentage vote, as intended.
To make things clear, Labour got 14% of the vote, and the Conservatives got 9% of the vote.
Alias says:
The fundamental assumption of the article is that human rights in the UK are better protected when enforced by a supranational institution like the EU than when enforced by the government (executive, parliament and judiciary) of the UK. That may or may not be true, but I don't see any evidence for that. Is there any particular evidence to show that human rights are better protected in large nations than in small ones?
It isn't enough to point to (for example) perceived deficiencies in the current UK government's approach to human rights. No-one claims that the UK government is fallible, or the EU's. For example, the article cites the EU's approach to asylum. Can one really claim that the conditions facing, for example, asylum seekers in refugee camps in Lesbos are a shining example of the EU's treatment of asylum seekers?
If the assumption were true, wouldn't the logical continuation be that we should strive for some kind of world government with real powers of enforcement? Is that what we want?
Culture and civil society
Exodus, Reckoning, Sacrifice: Brexit through the lens of myth
More British than European: Scots could reject independence once more
Northern Ireland faces rebordering after Brexit
How Brexit will affect disabled people's lives and rights
LSE European Politics & Policy

redpajama_set_name: RedPajamaCommonCrawl


Garden City Hospital has enhanced its billing system to offer you a quick and convenient method for paying your bills online, ePayment. . The process is simple, confidential and secure. Garden City Hospital accepts Visa, MasterCard, Discover, debit card and e-check.


text:
InVision Liquid Biopsy Platform
InVisionFirst-Lung
InVisionSeq
RaDaR Residual Disease and Recurrence
Inivata Insights
Inivata is a Leader in Liquid Biopsy
Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients
InVision® platform
Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
InVisionFirst®Lung
Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients
Radar™
A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
Discover Radar™
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Inivata Announces RaDaR™ Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
Inivata, a leader in liquid biopsy, today announced that it has received the CE mark for its RaDaR™ assay for the detection of molecular residual disease (MRD) and recurrence, having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC). In addition, Inivata has submitted to the MolDX program in the US for the reimbursement of RaDaR for clinical testing. Read More
Liquid biopsies for residual disease and recurrence
Jonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, Sarah-Jane Dawson, Esther Louise Moss, Ramaswamy Govindan, Iain Beehuat ... Read More
LBx 2022
Event expiration date display - 10 - 11 FEB 2022
Location: San Diego, CA Read More
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients' lives.
This is the story of the first patient Inivata tested.
Transforming the lives of Cancer Patients and Their Families
As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.
Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.
See our latest open roles
@inivata
We have a new white paper on RaDaR™, a highly sensitive & specific #ctDNA assay for the detection of molecular residual & recurrent disease (#MRD). To find out more about the #assay request a copy of the white paper here: https://www.inivata.com/about-us/contact-us/
We are proud to be partnering with the LBX #LiquidBiopsy Precision Oncology Summit in February. Join #TeamInivata & others in addressing the key challenges in progressing precision oncology pipelines by harnessing liquid biopsy technology.
Learn more here: https://lbx-summit.com/
Read our latest Med review titled 'Liquid biopsies for residual disease and recurrence' published in @CellCellPress
Inivata is a leader in liquid biopsy. Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients.
Our Global Locations
Research Triangle Park, NC, USA
Babraham Research Campus, Cambridge, UK
Company Reg: 9144647
CLIA No: 34D2113681
CAP No: 9469405
Licenses and Accreditation
INIVATA and InVision are UK, EU and US registered trade marks of Inivata Limited
TAm-Seq and InVisionFirst are UK and EU registered trade mark of Inivata Limited
InVisionSeq and eTAm-Seq are UK registered trade marks of Inivata Limited.
All rights reserved. Copyright © 2022 Inivata Ltd|Website Designed & Developed by Identity Creative
David Eberhard
David Eberhard, MD, PhD is Chief Medical Officer at Inivata. David is a seasoned healthcare executive, bringing over 20 years' experience in the research and development of oncology therapeutics, biomarkers, and diagnostics. He joins Inivata from Illumina, where he served as Senior Medical Director, Oncology, and was responsible for providing clinical expertise, strategic vision, and leadership to build the corporate and public presence of a new and rapidly growing medical oncology group. Prior to this he held the role of Senior Director, Oncology Development at Genomic Health, where he provided strategic and tactical support to bring oncology mutation testing to market, with a focus on the company's OncotypeSEQ, a liquid biopsy NGS gene mutation panel for solid tumors. David has been active as a consultant advising various biotech, pharma and VC clients on cancer drugs, diagnostic R&D and molecular pathology. He has also served as a pathologist in various lab-based roles, both within academia and industry, working on a variety of initiatives in oncology diagnostics, drug development and genomics.
David holds a Bachelor's degree in Biology from the University of South Dakota and a MD / PhD in Pharmacology from the University of Michigan. He carried out his Postdoctoral Research Fellowship in Pathology and Pharmacology at the University of Virginia and holds an American Board of Pathology Certification in Anatomic Pathology and Neuropathology.
Clive Morris
Clive Morris is President at Inivata. Following an early career as a surgeon, Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca's UK strategic R&D sites and global HQ.
He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Clive also founded and lead Health Innovation Manchester, and is a non-executive director of Wheatsheaf investments.
Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and trained as a physician at the University of Manchester in the UK.
Charlene Knape
SVP, Strategic Programs
Charlene Knape is SVP, Strategic Programs at Inivata and brings more than 25 years of experience and leadership in key areas including Clinical Affairs, Regulatory Affairs, Quality, Program Management and the Clinical Laboratory. Along her career path Charlene has held positions and executive roles at both start-ups and large corporations, including Kiyatec, Becton Dickinson, Micell Technologies, LabCorp, EndoTex, Somnus, and Avocet, covering a vast array of technologies focused in oncology, cardiovascular medical devices/combination products and the personalized medicine diagnostic space. Throughout her career, Charlene has participated in all levels of program teams bringing novel products to global markets, including USA, EU, and China, while working through multiple regulatory pathways, including FDA PMA/510(k), CE Mark and NMPA (formerly CFDA). Charlene comes from Toronto, Canada and holds a degree in Medical Laboratory Science.
Peter Collins
Peter Collins is Chief Business Officer at Inivata. Peter brings over 30 years of experience working in the biopharmaceutical sector, having held senior leadership positions in several molecular diagnostics companies, most recently at Guardant Health. Peter has also served as Chief Business Officer of Yourgene Health, where he led all aspects of commercialization and business development. Prior to this, Peter was Vice President, Head of Diagnostics at GSK – where he was responsible for the companion diagnostics assets and pipeline across all therapeutic areas, particularly oncology – and VP, Pharma Business Development at QIAGEN. Peter was also the founder and board member of Epemed, a European not for profit organisation bringing together global forces in personalized medicine. Peter holds a BSc in Biological Sciences from Plymouth University.
Alan Schafer PhD
Alan Schafer is Chief Technology Officer at Inivata. Alan brings to the role over 25 years of genetics and molecular diagnostics experience. He was previously CEO of 14M Genomics, a cancer molecular diagnostics company, and prior to that served as CEO of Population Genetics Technologies, a business specialising in infectious disease diagnostics and next-generation sequencing technologies. Earlier roles include those of Global VP Technology Development at GlaxoSmithKline and VP Genetics at Incyte. More recently, Alan has worked as an independent consultant for the biotechnology industry, academia and the investment community, offering his expertise in genomic and biology technologies with a particular focus on the interface between science, technology and business. Alan holds a PhD from the University of Southern California and has authored numerous publications in the molecular genetics field.
Rao Mulpuri PhD
Rao Mulpuri is Chief Operations Officer at Inivata. Rao is an experienced senior executive, bringing over 20 years of leadership expertise in the life sciences, specifically in the fields of diagnostics and genetics. Most recently, Rao served as COO of Provista Diagnostics, overseeing the strategic direction of the company to develop and commercialize liquid biopsy diagnostic tests. Prior to Provista, Rao was Vice President, Global Laboratory Operations at AssureRx Health where he set up global clinical laboratories (CLIA/CAP accredited) to commercialize molecular diagnostic tests. He also previously held various leadership roles at Beckman Coulter Genomics.
Rao holds a PhD and an MPhil in Physiology and Biochemistry from Vikram University, India as well as an MBA from the University of North Carolina, Chapel Hill's Business School, Kenan-Flagler. He is a named inventor in over 30 patents and has published 40 research manuscripts.
Charlie Kesinger PhD
Charlie Kesinger is Chief Information Officer at Inivata. Prior to joining Inivata Charlie led international technology operations for D-Wise, a consulting firm focusing on healthcare and life sciences. Before that he worked for Medsolutions, a billion-dollar healthcare-based decision support organization where he headed IT Excellence & Reliability.
Charlie has also served as a Chief Operations Officer at Emergisoft, a healthcare-based electronic medical records management company where he delivered systems to enterprise clients and successfully launched electronic medical records for maritime. Charlie has a PhD in Organizational Leadership. He attended Northwestern University to obtain a Master of Science (Medical Informatics). His undergrad is in Business Administration.
Robert Osborne
SVP, Technology and Assay Development
Robert Osborne is SVP, Technology and Assay Development at Inivata. Robert has more than 20 years of experience in research and development. Before joining Inivata in April 2019, Robert was a Principal Staff Scientist at the Wellcome Trust Sanger Institute where he developed new approaches to quantitate somatic variants in polyclonal tissues. Previously, he was Director of Technology Development at 14M Genomics and Director of Research at Population Genetics Technologies (PGT). Robert has authored 16 patents, including key early work on molecular barcoding technologies. Robert has a PhD in Genetics from the University of Nottingham and completed postdoctoral fellowships at the University of Rochester, NY and the University of Oxford.
Jamie Platt
Jamie Platt is Chief Operations Officer at Inivata. Jamie leads the global clinical laboratory operations and has extensive expertise in sequencing and molecular systematics, including population genetics.
During her 15 years in clinical diagnostics, Jamie has developed and validated numerous high complexity sequencing assays in the clinical areas of Oncology, Infectious Disease and Molecular Genetics and has introduced custom, industrial-grade automation to high complexity, sequencing assays.
She has spent more than 10 years overseeing development and validation of Next Generation Sequencing Assays for both clinical diagnostics and clinical trials and has special interest in applying advanced sequencing technologies (NGS) to improve personalized healthcare. Jamie received her PhD in Molecular and Cellular Biology from Oregon State University and completed postdoctoral training in population genetics at the University of California, Berkeley.
Nitzan Rosenfeld
Chief Scientific Officer
Nitzan Rosenfeld is Chief Scientific Officer at Inivata and is also one of Inivata's founders. He is a world-leader in circulating tumor DNA research and since 2009 leads a research group at the Cancer Research UK Cambridge Institute, part of the University of Cambridge. His work combines new molecular and genomics approaches to develop new diagnostic tools and applications. Previously he was head of Computational Biology at Rosetta Genomics, where he led development of molecular diagnostic tests for cancer. He originally trained in Physics, and specialized in quantitative molecular biology, obtaining a PhD in Systems Biology from the Weizmann Institute of Science, Israel. Nitzan has authored dozens of patents and research articles on methods for molecular diagnostics and cell-free DNA analysis.
For his contributions, he received numerous awards including the CRUK Future Leaders in Cancer Research prize, the Foulkes Foundation Medal, and the Pezcoller Foundation – EACR Cancer Research Award, and was elected as a fellow of the British Academy of Medical Sciences.
Jacqui Watson
Jacqui Watson is Chief People Officer at Inivata. Jacqui brings an extensive background of working internationally as an HR Director, People Developer, and consultant within various organizations at a senior level. She has over 20 years' experience of leading people and business transformation across different sectors including pharma, IT and hospitality.
Throughout her career Jacqui has focussed on inspiring individuals and teams to reach their full potential and in her current role she is responsible for the alignment of our organisational human resource processes to help drive our business success. She was most recently consulting for various companies, where her primary focus was to identify and develop a sustainable supply of leadership and talent from within these organizations.
Tim Shannon is Chief Financial Officer at Inivata. Tim manages finance, administration and legal activities. Prior to joining Inivata he formulated and implemented financial controls and process improvements supporting business growth and expansion most recently at Baxano Surgical and Talecris Biotherapeutics. His background in technology, life sciences, and distribution environments is particularly relevant as Inivata moves forward towards commercialization.
While at Talecris, Tim managed the Initial Public Offering (IPO) at a $3.28 billion valuation and has managed merger and acquisition transactions. Tim also has operational business experience across critical issues including budgeting, investor relations, systems implementation, and risk management. Tim has a Bachelor of Science in Business Administration from Appalachian State University and is a CPA, having spent the first 15 years of his career with PwC.
Stacy Chick
Stacy brings over 25 years of US healthcare commercial experience to Inivata. Joining the team as a consultant in early 2018, Stacy quickly leveraged her healthcare sales, marketing, market access and operations experience to build and accelerate the commercialization strategy for InVisionFirst®-Lung. Stacy was appointed Chief Commercial Officer effective September 1, 2018. Prior to joining Inivata, Stacy held sales, marketing, market access and general management executive roles leading teams in global and US life science companies including Bristol-Myers Squibb and Sanofi. Throughout her career Stacy was recognized with President's Club, Pinnacle and TWIN awards for outstanding business results, mentorship and patient advocacy. Stacy earned her MBA in Finance from Rutgers University and her BBA in Marketing from the University of Georgia. Stacy is an Emeritus Member of the Terry College of Business Alumni Board at the University of Georgia, Board Member of Our Brain Bank, and holds membership in the International Association for the Study of Lung Cancer (IASLC), Women's Business Leadership, Healthcare Businesswomen's Association, and the Leukemia & Lymphoma Society. She was appointed as a Peer Ambassador at Emory Winship Cancer Center in 2018.
Douglas M VanOort
Mr. VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. For seven months prior to October 2009, he served as Chairman of the Board of Directors, Executive Chairman and Interim Chief Executive Officer. Prior to joining NeoGenomics, Mr. VanOort was a General Partner with a Private Equity Firm, and a Founding Managing Partner of a Venture Capital Firm. From 1982 through 1999, Mr. VanOort served in various positions at Corning, Inc. and at its spin-off company, Quest Diagnostics, Inc. During the period from 1995 through 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Inc. which was then a $1.5 billion newly formed NYSE traded Company. During the period of 1989 to 1995, he held senior executive positions at Corning Life Sciences, Inc. including Executive Vice President. Corning Life Sciences, Inc. had revenues of approximately $2 billion and was spun-off in a public transaction to create both Quest Diagnostics, Inc. and Covance, Inc. From 1982 to 1989, Mr. VanOort served in various executive positions at Corning Inc., including Director of Mergers & Acquisitions.
Mr. VanOort currently serves as a member of the Board of Directors of several privately-held companies, and is a principal owner of a privately-held retail hardware store chain. Mr. VanOort is a graduate of Bentley University.
Robert Tansley
Robert joined Cambridge Innovation Capital as Investment Director in January 2014. After seven years working in hospital medicine, Robert joined the pharma industry in 1996 working in development and regulatory roles at Sanofi, the MHRA and Roche where he led the clinical team for the regulatory approval of Valcyte®.
Ten years ago, Robert joined the Cambridge based company Arakis and worked as Medical Director until its £106m sale to Sosei Inc. Since that acquisition, Robert has been involved in a number of start-up companies including founding the malaria-focused company Treague, being founding CEO of the University of Copenhagen spin-out Avilex Pharma and being part of the founding management team of KalVista which is developing the first plasma kallikrein inhibitor for diabetic macular edema in collaboration with its scientific co-founders from Harvard Medical School.
Robert qualified in medicine from University College London, he is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.
Craig Richardson
Craig is a Partner in IP Group's Life Science investment team. He started his career in the pharmaceutical industry in 1998 and worked in new product development for Glaxo Wellcome, followed by a series of business development roles in UK biotech. He was then part of the founding management team of an in vitro diagnostics company before moving into venture capital investment with Inventages, a life science focused VC fund. He subsequently worked for Fusion IP plc, a specialist investor in university spin-out companies, before joining IP Group in 2014.
Craig has a first-class honours degree in Pharmacy from Cardiff University and a PhD from the School of Pharmacy, University of Nottingham. He also holds an MBA with Distinction from the University of Warwick where he was awarded a Sainsbury Management Fellowship from the Royal Academy of Engineering.
Peter Wrighton-Smith
Dr Wrighton-Smith is the Chief Executive Officer and Founder of Oxford Immunotec Glob al PLC, a high-growth global diagnostics company focussing on monitoring immune-regulated conditions.
Peter has led Oxford Immunotec from the foundation stages, through product development to regulatory approval in over 50 countries, and subsequent worldwide commercialisation via both a kit and a CLIA lab model. Over that time, Oxford Immunotec has raised five rounds of venture funding prior to an IPO on NASDAQ in 2013. Dr Wrighton-Smith has a Masters in Engineering, Economics and Management, and a Doctorate in Medical Engineering, both from University of Oxford.
Jeanne Bolger
Jeanne joined Johnson & Johnson Innovation – JJDC, Inc as Vice President, Venture Investments, in February 2013.
She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne's responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.
Jeanne has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development. She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson's Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK. In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer's disease.
Jeanne received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.
Nitzan is one of Inivata's founders and its Chief Scientific Officer. He is a world-leader in circulating tumor DNA research and since 2009 leads a research group at the Cancer Research UK Cambridge Institute, part of the University of Cambridge. His work combines new molecular and genomics approaches to develop new diagnostic tools and applications. Previously he was head of Computational Biology at Rosetta Genomics, where he led development of molecular diagnostic tests for cancer. He originally trained in Physics, and specialized in quantitative molecular biology, obtaining a PhD in Systems Biology from the Weizmann Institute of Science, Israel. Nitzan authored dozens of patents and research articles on methods for molecular diagnostics and cell-free DNA analysis. For his contributions, he was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and the Academy of Medical Sciences Foulkes Medal.
Clive joined the leadership team in May 2016 and became CEO in July 2018. Clive worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and led the major transformation of AstraZeneca's UK strategic R&D sites and global HQ.
He has extensive experience across all phases of drug development including seven marketed or close-to-market oncology products. Most recently Clive founded and lead Health Innovation Manchester, to develop an innovation ecosystem involving the decentralisation of £6bn per annum of health and social care services. He is also a non-executive director of Wheatsheaf investments and the InnovateUK Medicines Discovery Catapult.
Clive is accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, has an Executive MBA and trained as a physician at the University of Manchester.
Jeff Buchalter
Jeff joined Inivata after a long and successful career in the bio/pharmaceutical industry most recently as Chief Executive Officer of Archimedes Pharma Ltd.
His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organisations. He brings extensive commercial and drug development experience in oncology and other therapeutic areas.
Jeff has been recognised for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field. He has also been a Collaborating Partner in the President's National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States.
Jeff received a Bachelor of Science Degree in Finance from Seton Hall University and a Master of Business Administration in Marketing from Temple University.
LinkedIn tracking code
Twitter tracking code


text:
Ochrotrichia membrana is een schietmot uit de familie Hydroptilidae. De soort komt voor in het Neotropisch gebied.

Schietmot uit het Neotropisch gebied

redpajama_set_name: RedPajamaWikipedia


In 2013, a bus from the Front Street Baptist Church in Statesville crashed on Interstate 40, killing six members of the parish. In addition, a semi-truck driver and another individual in an SUV that became involved in the accident were also fatally injured. The suits for wrongful death were filed in an Iredell County court, along with 12 personal injury claims by survivors. According to attorneys on both side of the litigation, a settlement was recently agreed to by the parties with undisclosed terms.
The accident occurred as the group was coming back from the annual Fall Jubilee event at the Gatlinburg Convention Center in Tennessee. The bus was a 1997 Metrotrans Europa Motorcoach model, which was owned by the church. Investigators found that a front tire failure had sent the vehicle spinning out of control. The defendant was the Hankook Tire Co. Ltd., a New Jersey-based manufacturer, who was alleged to have manufactured and designed a "negligent and defective" product that did not satisfy reasonable safety expectations.
Investigators think that possibly something had struck the tire prior to the blowout that may have weakened it. The set of tires had been purchased just over five years prior to the accident. Hankook attorneys attempted to place responsibility in the incident on the driver of the bus and church member, Randolph "Randy" Morrison. Morrison's wife was among those fatally injured in the crash and was included in this civil action. Five individuals were ejected from the vehicle during the crash.
Meanwhile, the plaintiffs contended that the defective tire was the lone cause for the accident. They explained that there was no evidence that the bus struck any other objects prior to the accident. Sergeant Bill Miller of the Tennessee Highway Patrol told reporters at the scene that the on-site investigation was thorough and that they "considered every possible scenario".
Hankook has grown to become a major supplier in the industry with production of 99 million tires in 2016 and annual sales internationally that are well into the billions. The suit further accused Hankook of a failure to warn those who purchased these tires of "dangerous characteristics" that existed, of which the company was aware of. The damages included major medical costs for injuries and ongoing costs associated with the event. The wrongful death suits asserted that just prior to their deaths, the deceased experienced "shock, fright and terror". The plaintiff attorneys said that many of the survivors should now have some degree of closure regarding the tragedy.
The plaintiffs at the time of the settlement were seeking a default judgment in the case based on the defendant's "concealment of crucial evidence" for approximately a period of two years. On two occasions during the three-years of litigation, Hankook attempted to have the case moved to a federal court. A plaintiff motion resulted in the case remaining in the Iredell County venue where the matter was ultimately resolved.


text:
2563 results for High Phyto
Results 1361-1380 of 2563 (ordered by syndrome)
PL-09-001
Cyanobacterial toxins effects
Gulf of Gdansk (Southern Baltic, Poland)
SE-88-005
Barsebäck-Lanskrona (Sweden)
Trelleborg (Sweden)
Gulf of Gdansk, Southern Baltic (Poland)
Aquia Creek, Virginia (Chesapeake Bay, United States)
Botnian Sea (Sweden)
Baltic Proper (Sweden)
Gulf of Gdańsk (Southern Baltic, Poland)
FI-14-001
Baltic Sea: South-western Finnish sea areas + northern Baltic Proper + southern Archipelago Sea (Baltic Sea: south-western Finnish sea areas +, Finland)
DE-08-001
Mecklenburg-Western Pomerania coast (DE-01; DE-02, Germany)
AU-01-002
Lake Alexandrina (South Australia, Australia)
Darling River (NSW, South Australia, Australia)
Peel-Harvey Estuary (Western Australia, Australia)
Orielton Lagoon (Tasmania, Australia)
Moreton Bay (Queensland, Australia)
Southern Baltic (Poland)
Pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129


As of tonight I believe I have worked out most of the remaining issues from the migration. There are still a few lingering characters to repair (Alex) and one potential lag issue that was observed during one of the wars today, but other than that things seem to be running smoothly.
Thanks for your patience during this much-longer-than-expected migration. We're excited to get back to normal development work again!
Page created in 0.01 seconds with 20 queries.


text:
Q: how can i choose which lines to print in file in java? i have this file name input.txt:
3 1

Hoa Lac, Thang Long, Le Quang Dao, Me Tri, Pham Hung, My Dinh, Cau Giay, Kim Ma, Hoan Kiem

Bus 74, Price 9000, Hoa Lac, Thang Long, Le Quang Dao, Me Tri, Pham Hung, My Dinh

Bus 99, Price 50000, Hoa Lac, My Dinh

Bus 34, Price 7000, My Dinh, Cau Giay, Kim Ma, Hoan Kiem

From: Hoa Lac, To: Hoan Kiem

i want to try to store each line as a String in array and i have write like this
  public static void readFile(){
        try {
            String data[] = new String[100];
            File myObj = new File("input.txt");
            Scanner myReader = new Scanner(myObj);
            int m;
            int n;
            m = myReader.nextInt();
            n = myReader.nextInt();
            System.out.println("m = " + m);
            System.out.println("n = " + n);
            while (myReader.hasNextLine()){
                int i = 0;
                data[i] = myReader.nextLine();
                System.out.println(data[i]);
                i++;
            }
        } catch (FileNotFoundException e) {
            System.out.println("cannot find file!");
            e.printStackTrace();
        }
    }

so far i can only read file and display all of them at once, but i can not control which line i want to print(ex:i want to print only line: 2 3 4),  please help me and explain to me please.

redpajama_set_name: RedPajamaStackExchange


text:
HomeCentral/Eastern EuropeIdeals of the May 3 Constitution still significant today
Ideals of the May 3 Constitution still significant today
May 3, 2019 Lithuania Tribune Central/Eastern Europe, HISTORY 0
Opening of a joint debate of Lithuania and Poland on the topic of the Constitution of May 3, 1791. @ Office of the Republic of Lithuania Robertas Dičkus
On May 2 the President Dalia Grybauskaitė met with Dainius Žalimas, President of the Constitutional Court of Lithuania, and Julia Przylebska, President of the Constitutional Tribunal of Poland and opened a joint debate of Lithuania and Poland on the topic of "The Constitution of May 3, 1791, its significance and lessons to Europe" press service of the Presidential palace informed.
The debate was held on the eve of the 228th anniversary of the Constitution of May 3. When addressing the participants of the debate, the President emphasized that the historic Constitution of the Polish-Lithuanian Commonwealth and the first written Constitution in Europe was our source of pride.
According to the President, this document became a part of the Lithuanian and Polish constitutional tradition and laid down the principle of constitutional supremacy as well as fundamental democratic principles of the rule of law.
Despite the complex situation of the time, initial reforms were aimed at progress and modernization of the state, helping resist external impact and preserve independence. Looking back we can already see the beginning of our road towards the future revival of our statehood.
According to the President, such reforms even if they were suppressed did not go without a trace. The Constitution of May 3 gave the people of Lithuania and Poland as well as the whole of Europe a unique ideological experience and values without which no state or society can exist. Therefore ideals of this political document are still relevant today.
The President also highlighted that it is very important to remember this shared historic and value-based connection between Lithuania and Poland which was reflected in the cooperation agreement between Lithuania and Poland signed 25 years ago.
The debate was attended by members of the Parliaments of Lithuania and Poland, diplomats, lawyers, and members of academia.
The initiative to hold a joint event between Lithuania and Poland on the Constitution of May 3 at the highest level emerged from the joint declaration on this important document that unites the two countries adopted by the two presidents a year ago.
Harbortouch is expanding in Lithuania
The heritage of the May 3 Constitution is in the spirit of European political compromise
Chernobyl the series: facts and fiction
Message from Lithuania to Ukraine: the most important support for you is in our hearts
On Belarus and its sovereignty
Lithuanian, Ukrainian presidents to meet on security issues
Lithuania now has substantial legal arguments to deny access for electricity produced in the unsa...
Lithuania, Poland to sign new deals on defense cooperation
Polish ForMin urges Lithuania to scrap election threshold for ethnic minorities – Interview
Some 50 people mark Russian-Georgian war anniversary at Russian embassy in Vilnius
Lithuanian formin calls for remembering lessons of Russian-Georgian war
Ex-political prisoners, deportees call on Russia to let Mission into Siberia
Ministry of Foreign Affairs moves for sanctions for human rights violations in Georgia
Navalny's aides covered protests in Russia online from Lithuania


You can count on Christmas fun!
Christmas is here and hopefully you are having a wonderful holiday. With all the excitement of the day, it can be a nice change of pace to sit down with your little one and have a few moments of quiet fun together. These Christmas math worksheets can definitely entice your child to practice skills and she is sure to have fun!
Christmas is almost here and the hectic days leading up to the holiday are nearly over. Now you have time to relax and enjoy your family. It may be the perfect opportunity to spend some quiet time with your little one. The Christmas illustrations on these Christmas worksheets will hopefully engage your child while he hones some important school skills.
With Hanukkah just underway, it is a great time to have some fun with Hanukkah math worksheets that feature colorful Hanukkah symbols. Counting is a natural activity during Hanukkah as children count the candles for the menorah or count coins or nuts as they play with the dreidel. So why not add some math related activities with worksheets that use colorful Hanukkah symbols!
With Thanksgiving behind us and December under way, the focus of television programming and retail advertising immediately shifts to the Christmas holiday. This year, however, the eight day Hanukkah celebration starts the week before Christmas and actually ends on Christmas day. If your family celebrates Hanukkah, you have likely begun talking about the holiday with your children. It is easy to add some learning opportunities to time spent with your child by introducing worksheets with the Hanukkah theme. If your family does not celebrate this holiday, these Hanukkah worksheets can be a chance to introduce your child to Hanukkah and some of its symbols while he hones important preschool skills.


To find out when your trial will end or when you will next be billed for your subscription, you need to look up your subscription details on the platform where you originally subscribed to Lifetime Movie Club.
If you subscribed via our website, log in to your account at https://www.lifetimemovieclub.com. Your account details page will show you when your next payment is due, along with options to update your credit card information, view your billing history, change from a monthly to an annual plan, or cancel your subscription. If your account is currently inactive, you will see an option to reactivate your subscription.
If you are unsure which platform you originally subscribed on, sign in to your account at lifetimemovieclub.com, click your name in the upper right corner and select 'My Account.' Your account details page will show you which platform you are subscribed through and you can proceed with the instructions above to find your subscription information.


text:
package example.repo;

import example.model.Customer244;

import java.util.List;

import org.springframework.data.repository.CrudRepository;

public interface Customer244Repository extends CrudRepository<Customer244, Long> {

	List<Customer244> findByLastName(String lastName);
}

redpajama_set_name: RedPajamaGithub


This is a radio documentary on the experience of being insane, with text drawn from the autobiographies of schizophrenics. The music showcases the hallucinations and delusions of madness as the speakers describe the world of insanity – from the inside out. This was Alex Randall's undergraduate thesis at Princeton University in 1973.


Have you ever wondered about all those fancy Greek and Latin terms that some Christians throw around? Perhaps not. If you're not one of those people who wonder what the heck people mean when they say things like "hypo-static union" or "orthopraxy" then you'll probably not find much interest in this.
If, however, you do have some inkling of curiosity about those things, you might be interested in this post. While this is not going to be an exhaustive list, it does contain some of the more commonly used terms. Also, in some cases, this may not reveal everything you want as I don't intend to get involved in-depth on some of the deeper meanings and implications of these terms. Rather, it's just a quick primer of some of the terms I've come across in the last few years that made me wonder what they meant.
Orthodoxy – This comes from two Latin words which break down as "ortho" or "right" and "doxy" meaning "belief." So, this is the concept of "right belief" or believing the right things. Usually this is applied to commonly accepted truths about faith and theology.
Orthopraxy – This one is obviously quite similar, but the "praxy" refers to "practice." In other words, this would refer to doing the right things. Often it's thought of as an extension, or result of, orthodoxy.
Hermeneutics – This essentially is defined as the science/art of biblical interpretation. Everyone who does any sort of Bible study tends to have their own hermeneutic which has a lot to do with paradigms and perspectives. Though there are certain hermeneutics that are more general, such as "authorial intent" which tries to interpret the Bible based on what the original author's intent was in writing a particular statement or work.
Sola Fide – This phrase means "Only Faith." It is the Reformed doctrine of salvation by faith alone, and not by works.
Vulgate – This term is pretty widely used and you may be familiar with it. It is the term used to describe the Latin translation of the Bible. Remember that the original texts were written in Hebrew, Aramaic and Greek.
Imago Dei – This is translated as "Image of God." It is used to describe the creation of Man in God's image. Christian doctrine holds that all human beings "carry" the Image of God.
Eschatology – This is the study of the "end times." That's the short version, though there is a great deal of teaching and doctrine around this type of study. Often, it refers to a type of biblical interpretation, or hermeneutic, based on how scripture addresses the end times.
Christology – This, of course, is the study of the Messiah. Many scholars use this as a hermeneutic to study Old Testament scripture in light of the revelation of Christ. They look at OT writings and attempt to interpret them by seeing, or potentially seeing, references to Christ.
Christos – This, of course, refers to Jesus Christ. The word is derived from the Greek translation of the Hebrew term for Messiah. Since the New Testament was written almost exclusively in Greek, this explains why the term has been so commonly accepted as opposed to using a Hebrew derivative.
Logos – Again, typically a reference to the Christ. It actually means "Word" or "Speech" or at least consistently has that idea. The popularity of using this term for Christ probably came from the fact that John's Gospel refers to the "Word" in reference to Jesus.
Hypo-static Union – This is a fun one. This refers to the idea that Jesus was simultaneously fully God and fully Man. This is a necessary attribute of Christ as without it, it drastically impacts our idea of salvation. You are encouraged to study this one further elsewhere as there is a great deal of theology and doctrine built on this concept that I won't have the time to cover here.
Homousios – This term was arrived at during the first Ecumenical Council at Nicaea. It refers to the idea the Jesus was of "the same substance" as God the Father. This term helped the church fathers at the time develop what we now know as the Nicaean Creed which affirms the doctrine of the Trinity.
That should be about enough for most people. Plus, I can't think of any other terms off the top of my head. If there are any Greek or Latin terms that haven't been listed here that you think should be included, please feel free to leave your comments and suggestions. Also, most of the definitions I have provided are based on my own informal study, so if any linguistic scholars deem these definitions somehow insufficient or inaccurate, please feel free to correct me.
At the very least, I hope this helps to un-confuse some of the rhetoric you might hear thrown about in Christian circles. And, perhaps it will help to encourage someone to look more into these concepts, where they came from, why they have been defined as such, etc.


When you need some reliable, convenient, and above all professional help outdoors, Allan's Gardeners are standing by. Your service will feature skilled gardening experts local to Mortlake SW14, full training for all fully insured staff, and a host of top of the range equipment provided at no extra charge.
We're Your One-Stop Garden Maintenance Shop in Mortlake!
You can get professional gardening and other services from us in more than just Mortlake. Find experts in… Putney, Streatham, Upper Tooting, Tooting Broadway, Earlsfield.


text:
5 Defense Stocks to Buy to Toughen Up Your Portfolio
By Harriet Lefton, Contributing Writer | September 30, 2019
Hold on to your hats, brace yourself for an uptick in volatility … and perhaps give defense stocks a look this October.
Goldman Sachs' equity derivatives strategist John Marshall, in a recent report to clients, writes that, since 1928, volatility has been 25% higher on average during the month of October.
"Not only are earnings day moves rising relative to average daily moves, but October tends to be the quarter with the largest absolute earnings day moves for U.S. stocks," Marshall writes. And it's no coincidence. "We believe it is a critical period for many investors and companies that manage performance to calendar year-end."
How should investors play this potential bout of choppiness? Get defensive – with defense stocks. Aerospace, defense and other companies that have a hand in national security are traditionally more defensive investments. They also offer notably low exposure to Chinese trade war tensions.
Encouragingly, the iShares U.S. Aerospace & Defense ETF (ITA) is currently trading up 30% year-to-date. That's better than the S&P 500 (+18% YTD) and Dow Jones Industrial Average (+15%).
Here are five intriguing defense stocks to buy for … well, defense. We turned to TipRanks for analyst ratings across the industry. All five of these stock picks score a Moderate Buy or Strong Buy consensus based on ratings from the last three months.
SEE ALSO: 20 Dividend Stocks to Fund 20 Years of Retirement
Data is as of Sept. 29.
Kiplinger's Latest Online Broker Rankings
5 Defense Stocks to Buy to Toughen Up Your Portfolio | Slide 2 of 6
CACI International
Market value: $5.7 billion
TipRanks consensus price target: $250.00 (10% upside potential)
TipRanks consensus rating: Moderate Buy
CACI International (CACI, $227.50) provides information solutions and services to support national security missions. For example, to address the growing threat posed by drones, CACI's SkyTracker Technology Suite can covertly detect and track unmanned aircraft systems (UAS).
At CACI's recent investor day, management revealed that its key focus now comes from driving growth through its mission technology offerings, which currently account for about 30% of product revenue. CACI estimates mission technology has a $90 billion total addressable market (TAM) that will grow at an impressive 6% annually over the next five years – that's three times as fast as the estimated 2% CAGR for the company's enterprise business, which has an estimated TAM of $130 billion.
Credit Suisse's Robert Spingarn applauds that decision. "Mission technology (a ~$1.7B business now) has higher market growth, higher margin potential, and is a top priority for the (Department of Defense) customer – making it an understandable choice for management's focus," he writes. His Outperform rating (equivalent of Buy) comes with a Street-high $269 price target that implies 18% upside potential from current prices.
Multiple analysts reiterated their bullish calls on CACI after the event. Most notably, Goldman Sachs' Gavin Parsons boosted his Buy rating to a rare Conviction Buy. That rating is given to equities that Goldman holds in particularly high regard, making CACI among the top defense stocks to buy at the moment. The analyst cited his expectation for "accelerating organic revenue growth to drive higher estimates."
This positive review came alongside a $258 price target, suggesting 13% upside from here. See what other top analysts have to say about CACI on TipRanks.
SEE ALSO: How to Retire on $500,000
Market value: $215.4 billion
TipRanks consensus price target: $419.00 (9% upside potential)
Boeing (BA, $382.86), largest among defense stocks, currently garners a Moderate Buy consensus from the Street. No doubt, it's an expression of cautious optimism as analysts wait to see what happens next with the company's 737 Max. The fastest-selling plane in Boeing's history was grounded in March after two fatal crashes killed a total of 346 people.
The latest? Boeing CEO Dennis Muilenburg said in mid-September that "a phased ungrounding of the airplane amongst regulators from around the world is a possibility."
Credit Suisse's Robert Spingarn expressed optimism a week before Muilenburg's comments, writing, "We continue to expect that the plane will return to service eventually, and reiterate our long-term positive view and Outperform rating on Boeing."
Morgan Stanley's Rajeev Lalwani has gone one step further. He calls BA his "top pick" in the aerospace and defense industry and sees a "clear path" for shares to reach $500 (31% upside potential). The analyst points out Boeing's strong balance sheet, and that the company has managed to retain "meaningful leverage to mitigate liquidity risks."
"The combination of a healthy free cash flow yield, a stable commercial aerospace backdrop, and positive upcoming data points" are more bullish points. Lalwani is forecasting annual earnings per share (EPS) growth of 10% to 15% (vs peers at under 10%) beyond 2020, and he argues that the grounding "creates a buying opportunity while the aerospace cycle is steady." You can check out other current pro opinions on BA at TipRanks.
SEE ALSO: The Best Vanguard Funds for 401(k) Retirement Savers
Market value: $16.7 billion
Heico (HEI, $124.74) is a rapidly growing aerospace and electronics company, and its focus on niche markets stands out among defense stocks. Shares have surged 61% year-to-date, and while some analysts are wary at these levels, others argue that HEI's lofty valuation is justified.
Interestingly, while the stock scores a cautiously optimistic Moderate Buy consensus from all analysts, it garners a more bullish Strong Buy consensus over TipRanks' top-rated analysts. For instance, five-star Credit Suisse analyst Robert Spingarn (Outperform) anticipates consistent annual EPS growth of about 16% between 2018 and 2021.
"Though valuation remains in the stratosphere, we continue to believe that HEI's exceptional execution, compounding cash flows, and solid M&A track record warrant a sizable premium," Spingarn writes. He made the call after Heico reported a "beat-and-raise" quarter and sustained its recent streak of blockbuster organic sales growth.
Spingarn reiterated his Outperform rating and boosted his price target on the defense stock from $133 all the way to $163. That indicates 31% of additional upside potential from here. The analyst is confident that Heico can continue to outgrow its addressable market thanks to new product introductions, greater customer penetration and an expanding client base. "HEI's long-term focused investor base appears willing to hold the shares despite the valuation," he writes, suggesting to buy on any weakness. Find out how the Street's average price target for HEI breaks down.
SEE ALSO: 25 Dividend Stocks That Analysts Love the Most
Keep a close eye on aircraft manufacturing giant United Technologies (UTX, $136.39). The company is on the cusp of a whopping $50 billion merger with major U.S. defense contractor Raytheon. If the "merger of equals," announced in June, receives approval at special shareholder meetings in October, the result will be a new aerospace and defense powerhouse boasting $74 billion in 2019 pro forma revenues.
"We like the proposed RTN merger for technology synergies and enhanced financial flexibility," top Cowen analyst Cai von Rumohr writes. Shareholder approval seems likely given diminished activist resistance, he argues, and the Defense Department appears to support the deal.
But this is a "win-win" situation, because von Rumohr is a fan of UTX with or without Raytheon. He says if the merger doesn't go through, United Technologies should move closer to its estimated sum-of-the-parts valuation of $155 to $160 per share, "since UTX Aero will be the last large cap commercial aero systems 'pure' play." That would be 17% upside at the high end of the range.
Von Rumohr also believes investors are underappreciating major cyclical turns at Otis (the elevator division) and Pratt (the aerospace division), as well as United Technologies' recession-resistance. Discover more UTX insights from the Street at TipRanks.
SEE ALSO: 10 Emerging-Markets Stocks That Will Survive the Trade War
Kratos Defense & Security Solutions
TipRanks consensus price target: $26.25 (43% upside potential)
TipRanks consensus rating: Strong Buy
Kratos Defense & Security Solutions (KTOS, $18.37) specializes in unmanned systems. This includes everything from satellite communications to cybersecurity to missile defense and hypersonic systems.
It also has the highest implied potential upside among the defense stocks on this list, at 43%. That's in part because of a significant drop in the face of Kratos losing out on a hypersonic test drone contract award to Northrop Grumman (NOC), and despite second-quarter sales and earnings that beat the analyst consensus.
Top-rated B. Riley FBR analyst Mike Crawford is particularly excited about the company's prospects when it comes to unmanned aerial vehicles (UAVs). For instance, Crawford notes that demand for Kratos' Valkyrie – an experimental stealthy combat drone that completed its first flight in March 2019 – "continues to both firm and expand."
The analyst says the Defense Department has moved beyond the question of whether UAVs make sense, and is instead considering operative questions about how to integrate these tactical vehicles into the fleet. That means enabling the machines with sensors, payloads, datalinks and artificial intelligence.
"KTOS, as an early mover and clear leader in the low-cost, tactical UAV space, stands poised to capitalize on its investments in proprietary IP and capabilities, and we believe shareholders will continue to be rewarded by this investment," Crawford writes. He reiterated his Buy rating two months ago, listing a $26 price target that implies 42% upside from here. Get the full scoop on Kratos Defense's analyst consensus at TipRanks.
Harriet Lefton is head of content at TipRanks, a comprehensive investing tool that tracks more than 5,500 Wall Street analysts as well as hedge funds and insiders. You can find more of their stock insights here.
SEE ALSO: The Best Online Brokers
The Kiplinger Washington Editors, Inc., is a wholly owned subsidiary of Dennis Publishing, Ltd.


text:
Filled with illustrations, photographs, artwork, historically accurate caricatures, and little-known facts, Rosa Parks introduces readers to a woman whose defiant action became a key event in the Civil Rights Movement. On December 1, 1955, Rosa Parks was ordered to give her seat to a white man, and she was arrested for refusing. Raised to stand proud, even when being harassed and discriminated against, Parks showed her fellow African Americans that they too could stand up for their rights.
The History Maker Bios series offers introductions to the lives of historical figures found in the core of every history curriculum. Filled with fascinating true stories and illustrations, photographs, artwork, and historically accurate caricatures, each title in this lively series will entertain and inform readers.
Maryann says
In 1999, Rosa Parks was honored with the Congressional Gold Medal of Honor for being the "Mother of the Modern Day Civil Rights Movement." Though Rosa never bore a child, she was a mother in many ways. She saw her role in life as one of service—but not in a demeaning sense. She simply strove to be helpful. She possessed a deep spirituality that taught her to be on the alert for opportunities to serve. She found such an opportunity when she said "No." That one word changed the course of United States history.
It takes a special courage to be a writer, for writers—whether we pen fiction or fact—must tell the truth. When I think about how I can be helpful in my daily life, I remember Rosa Parks and the courage she embodied. May her spirit and fortitude guide us all in writing and speaking the truth. Do not be afraid!
illustrated by Tim Parlin
Carolrhoda Creative Minds
find the book
You can find this book at your favorite library or used books shop.


We are family run business based in Wolverhampton, and we have been in operation for over 20 years.
We pride ourselves on our reliability and high quality service. We can meet demands of both large and single orders.
At all times we have 100 tonnes of finest quality steel, 43a and 50b in stock.
Our CNC profiles cutting machine can cut steel from 5mm to 150mm thick, and to a length of 6000mm width 2000mm.
We have the facilities to Lumsden Grind 100" corner to corner. These can be ground to either a specific size, or to clean up your steel blank.


Describe how you capture and evaluate outcomes, and include the results you have achieved.
Discuss the measures your program tracks, including process measures, health outcome measures and costs.
Describe how you track asthma patients (e.g., through an asthma registry, electronic medical records or other system to collect and analyze information on patient diagnoses, treatments, referrals, interventions, health care utilization and outcomes.
If you have data specific to the effectiveness of in-home interventions, include this information.
Describe the results you can attribute to your environmental asthma management activities.
Program tracks process measures (e.g., appropriate use of asthma medications, primary and specialty care visit rates).
Program tracks health outcome measures, such as reduced hospitalizations and ER visits, improved quality of life and symptom-free days.
Processes and procedures are incorporated into the program's design to ensure that evaluation (i.e., data collection and analysis) is a routine part of the asthma program.
Example:"LA Cares About Asthma® annually measures HEDIS data on the Use of Appropriate Medications for People with Asthma and analyzes the data in comparison to previous years. Reports are generated by geographic region, age of members and asthma severity level. The ADM registry is used to track members on a monthly basis. Monthly reports including new members, current members and stratification changes are generated from the ADM to facilitate member interventions."
Program management includes analysis of costs or return on investment.
Example:"On average, participants had a savings of $3,833 per participant ($319 PMPM)."
Program has achieved cost savings or positive return on investment compared to a baseline measurement.


. NEW NISSAN GT! gtr drawing profile! Man Profile Drawing at GetDrawings: Pixilart! unicorn profile drawing? Human Profile Drawing at GetDrawings! Female side profile base by UnseenIvy on DeviantArt? Beardageddon? Beard Drawing Man Goatee Art free commercial clipart? BEARD SURVEY: Beard Biker: man.


text:
BOYS BASKETBALL: Heralds' frantic rally comes…
BOYS BASKETBALL: Heralds' frantic rally comes up just short
By The Inland Valley Daily Bulletin | dailybulletin@dfmdev.com |
PASADENA – It was important for the Maranatha High School boys basketball team to get off to a strong start, Minutemen coach Tim Godley said.
The Minutemen did, and therein lies what proved to be the inevitable.
Maranatha jumped to an 11-point lead and later withstood Whittier Christian's frantic effort in the waning seconds to hold on for a 57-55 win in an Olympic League thriller Tuesday night.
Whittier Christian (18-6, 4-1) never led or tied the game, but the Heralds did come close as they frantically put together a late charge.
Miller Brown carried them the entire night and scored nine of his 22 points in the fourth quarter.
Whittier Christian's Chris Joseph, who finished with 19 points, hit a 3-pointer with 39 seconds left in the game. Maranatha's Stephen Van Spronsen hit an 8-foot jumper on the ensuing possession to give the Minutemen their final basket.
Whittier Christian coach Sherwin Durham drew the final play for Brown, who was isolated on the wing. On the outlet pass Brown drew two defenders. He got off a shot, but it bounced off the back of the rim.
Maranatha's Jeremy Major battled for position and ultimately the rebound before being fouled with two seconds left. He missed the one-and-one before Brown grabbed the rebound with one second left in the game.
The Heralds' length-of-the-court shot missed the rim, giving Maranatha (19-5, 5-1) a gritty win and a half-game lead for first place in the league standings.
Maranatha opened the first quarter on a 7-0 run thanks to Josh Chamberlain, who scored 10 of his game-high 24 points in that quarter.
"We needed a first half like that," Godley said. "We knew we didn't play well the first time at their place. That was a catalyst for us.
"We got mad with how poorly we played."
Van Spronsen's relentless attack on the glass paved the way for numerous second-chance opportunities for the Minutemen. He finished with 11 points, 14 rebounds and three blocked shots.
"He's our leader and he's right there with you," Godley said. "He does everything we ask of him and he does it well."
Durham didn't need much time to pinpoint where the Heralds lost the game.
"We knew we didn't show up in the first half," he said. "We thought we'd come back and pull this one out."
Mario Zamorano contributed seven points for Whittier Christian.
Major had a relatively quiet night for Maranatha, but others picked up the slack, including RJ Straker (eight points), Ryan Holstein (seven points) and Andrew Elffers (five points).
Major was quiet, but he had a reason. He's been battling the flu and did not practice the night before.
Major sat out most of the second quarter, but his presence was felt in other areas. He finished with six steals. The 5-foot-9 sophomore point guard nearly gave Maranatha a huge momentum swinger if not for a missed dunk off a steal and fast break.
"At that point, you let it happen because you have the lead and some cushion," Godley said. "I wasn't upset. He's going to dunk in games.
"He might as well start doing it now."
miguel.melendez@sgvn.com
626-578-6300, ext. 4485
The Inland Valley Daily Bulletin


In part one of this blog series we shared some great cook school and food experiences that Scotland can offer. This time, things get even hotter as we introduce you to some hot Highlanders and the hottest accommodation for 2012 incentive travel.
Introducing your guests to some true Scottish Highlanders who will share their passion and emotion about their beloved country! It's guaranteed to leave them with fun & fond memories of their time in Scotland!
Highland Games Highlanders - Our team of Highlanders will show you what it takes to be Scottish as they demonstrate and supervise Highland Clan Games for your group.
Wild Harley Highlanders - These hunky Harley Davidson motorbike Highlanders are a real treat to surprise guests with at any point during their program!
Highlander Hijack - Have your group's coach hijacked mid-journey by a crazed Highlander on a motorbike! A memory your group will never forget!
Share a Dram with a Highlander - No glitz, glam or fancy motorbikes, just simply kicking back and sharing a dram of whisky and hearing stories of Scotland's wild and wonderful past.
Scotland offers a fantastic array of 4* & 5* accommodation to suit all kinds of tastes and budgets.
Below are our top 3 favourites for 2012 travel.
This really is a small sample of the accommodation that Scotland has to offer!
Our Project Managers' have a wealth of knowledge about all kinds of accommodation, from Highland Castles, to glamorous camping and boutique city hideouts… all you need to do is ask!
Up next time - The hottest venues for lunches, dinners meetings and awards, plus, red hot transfer options that make a necessity an experience to remember!


Intricate carving surrounds this mirror of beveled glass.
Reflecting the light of any room, this beveled glass mirror is beautiful on its own or mounted directly on a double chest.
A small turned finial tops this beveled glass mirror.


text:
Awards News
Comings & Goings
Daytime TV Ratings
DVR Ratings
The Locher Room
'The Talk' Co-Host Akbar Gbajabiamila to Appear on 'The Bold and the Beautiful' – FIRST LOOK PREVIEW
'The Bold and the Beautiful' Will Dedicate An Upcoming Episode In Memory of the Late Betty White
Soap Opera Ratings Report for the Week January 3-7, 2022
Daytime Broadcast Ratings for the Week of January 3-7, 2022
TODAY: 'The Bold and the Beautiful' Stars Thorsten Kaye and Lawrence Saint-Victor to Guest on 'The Talk'
Writers Guild Awards Nominations Announced: 'Days of our Lives', 'General Hospital' and 'The Young and the Restless' Competing
Daytime Broadcast Ratings for the Week of December 27-31, 2021
Tag: Francesca James
Former 'AMC' Actor Facing Strange Accusations Regarding Julie Harris' Death Wishes
"All My Children" actress Francesca James (ex-Evelyn Johnson) is in the middle of a plot fit for a thriller film. According to The New York Post, the Emmy winner was named co-executer of the estate of recently deceased Broadway star Julie Harris, and friends and former employees of the Tony-winner are accusing James of "worming" her way into Harris' life, taking control of her business and medical affairs and alienating her from her son, Peter Gurian — all so she could inherit part of Harris' estimated 10 million fortune!
Posted by Kambra Clifford Monday, December 2, 2013
Full 'All My Children' Cast List Revealed!
The OnLine Network (TOLN) has confirmed the following stars who have joined the cast of "All My Children." As previously reported, "All My Children" and "One Life to Live" began production on Monday, February 25 in Stamford, CT for new episodes scheduled to release later this spring on Hulu and iTunes. Today, The OnLine Network (TOLN) announced the following contract cast for the reboot of "AMC":
Posted by Errol Lewis Wednesday, February 27, 2013
Former 'Somerset' and 'Love of Life' Star Gene Bua Passes
On Saturday, November 17, 2012, Gene Bua ("Somerset," "Love of Life" and "How To Survive a Marriage") passed away after battling Parkinson's disease for the past 13 years according to a posting on the actor and his wife Toni's website Bua Acting for Life. "The great Master Teacher and my hero and Lion King for 47 years, Gene Bua, passed into the Light on Sat. Nov. 17th at 1:40, after battling 13 years of Parkinson's and yet still going on to teach, write songs, be a mighty friend, and enjoy much of his life. I am surrounded by his power, love and radiance as I walk through these coming days with as much Grace as God will allow me. Very much love to you all," said Mrs. Bua of her husband on the website.
Posted by Errol Lewis Sunday, November 18, 2012
Editor's NotebookNews
Soaps: This is Your Life, New Documentary Paints Picture on Dying Genre
Last summer I was lucky enough to be included as an interviewee in the new soap opera themed documentary appropriately titled "Soap Life," which follows the life, and possible death, of daytime soap operas. I can't believe I forgot all about it and didn't realize it until this morning!
Posted by Errol Lewis Tuesday, April 10, 2012
© 2001-2021, Soap Opera Network. All Rights Reserved.


As had been speculated, the brief run of the Aston Martin Virage is over with the arrival of the 2013 Aston Martin DB9, shown above. You'll recall that the Virage was introduced as a bridge between the previous DB9 and the now-defunct DBS.
Coupled with the arrival of the new range-topping Vanquish, the '13 DB9 eliminates the middle man, so to speak, merging the Virage's styling elements (as evidenced by the DB9's front fascia) with powertrain and chassis tweaks developed for the Vanquish.
You will doubtless note that the DB9 looks like nearly every recent Aston Martin preceding it. We'd agree, while allowing that the familial look is a feature, not a bug. As before, it's offered as a coupe or convertible (Volante).
Power in the new DB9 comes from the latest version of Aston Martin's 6.0-liter V12, making 510 horsepower and 457 pound-feet of torque in this application. Those are increases of 40 hp and 14 lb-ft over the old DB9, as well as 20 hp and 37 lb-ft over the Virage. Carbon-ceramic brakes are standard, and the car boasts 50/50 distribution of its 3,935-pound curb weight. If you want to shift for yourself, you'll have to make do with the Touchtronic 2's paddles, as there's no traditional manual gearbox offered.
Inside, you'll find the same familiar instrument and control layout featured in the current Vantage and the outgoing DB9 and Virage models. A backup camera is now standard. The new DB9 does not receive the updated interior design that premiered in the 2013 Vanquish, so there's now a clear differentiation between the flagship and the "mainstream" V12 car in that respect.
If you want to order a new DB9, you may do so immediately. Pricing starts at $185,400 and it hits showrooms in November. For the full rundown, you can view the entire PR blast from Aston Martin below.